Accéder au contenu
Merck
Toutes les photos(1)

Principaux documents

Voir toute la documentation

A0362

Sigma-Aldrich

Adjuplex™ Vaccine Adjuvant

Concentrate, sterile

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Code UNSPSC :
12352200
Nomenclature NACRES :
NA.25
Le tarif et la disponibilité ne sont pas disponibles actuellement.

Stérilité

sterile

Qualité

NOT FOR HUMAN USE

Conditions d'expédition

wet ice

Température de stockage

2-8°C

Description générale

Adjuplex potentiates immune responses to vaccines without reactogenicity and has demonstrated superiority to alum, Freund′s adjuvant, Ribi-R730 and numerous other experimental adjuvants. In laboratory animals, Adjuplex has been shown to improve the protective immune response to a variety of experimental human vaccines including HIV, influenza, rotavirus and malaria.

Application

Adjuplex is suitable for use with all types of antigens such as whole organism (live or inactivated), protein, polysaccharide, DNA, virus vector, and VLP. It is suitable for all routes of administration including intramuscular, subcutaneous, intradermal, and mucosal including intranasal.
Adjuplex™ Vaccine Adjuvant has been used to study the effects of adjuvants for DNA vaccination.[1]

Autres remarques

Adjuplex Vaccine Adjuvant is a non-denaturing adjuvant that does not contain oils, detergents, preservatives, or components of animal or bacterial origin. Adjuplex is is non-immunogenic and free of allergens, enzymes, mercury, aluminum, and other metals.

Quantité

One ml of Adjuplex is sufficient to formulate ten 0.5 ml doses of vaccine.

Informations légales

Adjuplex is a trademark of Advanced BioAdjuvants, LLC

Pictogrammes

Exclamation mark
GHS07

Mention d'avertissement

Warning

Mentions de danger

H319

Classification des risques

Eye Irrit. 2

Code de la classe de stockage

12 - Non Combustible Liquids

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number
SLBS7160
SLBR0940V
SLBP5255V
SLBN2346V
SLBM1261V

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Rechercher un(e) COA

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

  1. Which document(s) contains shelf-life or expiration date information for a given product?

    If available for a given product, the recommended re-test date or the expiration date can be found on the Certificate of Analysis.

  2. How do I get lot-specific information or a Certificate of Analysis?

    The lot specific COA document can be found by entering the lot number above under the "Documents" section.

  3. How do I find price and availability?

    There are several ways to find pricing and availability for our products. Once you log onto our website, you will find the price and availability displayed on the product detail page. You can contact any of our Customer Sales and Service offices to receive a quote.  USA customers:  1-800-325-3010 or view local office numbers.

  4. What is the Department of Transportation shipping information for this product?

    Transportation information can be found in Section 14 of the product's (M)SDS.To access the shipping information for this material, use the link on the product detail page for the product. 

  5. What is used to solubilize Adjuplex ™ Vaccine Adjuvant reagent, Product A0362? 

    The Adjuplex™ Vaccine Adjuvant reagent (Product No. A0362) can be solubilized in a sterile diluent such as phosphate buffered saline (PBS).  Endotoxin-free Dulbecco’s PBS without Ca2+ and Mg2+ is recommended, while unbuffered normal saline is NOT recommended.

  6. What are the adjuvant components of the Adjuplex™ Vaccine Adjuvant reagent, Product A0362? 

    The formulation of Adjuplex™ Vaccine Adjuvant reagent (Product A0362) is proprietary.  The formulation does not contain any components of animal-origin, microbial origin, or from recombinant technology.

  7. What is the recommended volume dose used with Adjuplex™ Vaccine Adjuvant reagent, Product A0362? 

    In general, the dosage volume of Adjuplex™ Vaccine Adjuvant (Product A0362) combined with antigen should be comparable to the dosage volumes used for other adjuvants.  Typical volumes are 0.1-0.2 mL for mice, 0.5 mL for rats and guinea pigs, and 1 mL for rabbits and goats, but these volumes are guidelines only.   For best effect, a dose response curve should be prepared.  

  8. What methods of administration are recommended for antigen preparations using Adjuplex™ Vaccine Adjuvant reagent, Product A0362? 

    Adjuplex™ Vaccine Adjuvant (Product A0362) has been found to be suitable for all routes of administration, including intramuscular, subcutaneous, intradermal, and mucosal including intranasal.  

  9. What types of antigen may be used with Adjuplex™ Vaccine Adjuvant reagent, Product A0362? 

    Adjuplex™ Vaccine Adjuvant (Product A0362) is suitable for use with all types of antigens including whole organism (live or inactivated), protein, polysaccharide, DNA, virus vector, and VLP antigens.  

  10. Can prepared solutions of antigen and Adjuplex™ Vaccine Adjuvant reagent, Product A0362, be stored and reused?

    We do not recommend reusing diluted solutions of Adjuplex™ Vaccine Adjuvant reagent (Product A0362) due to risk of contamination.  We recommend preparing fresh dilutions of Adjuplex™ Vaccine Adjuvant reagent with antigen each time prior to use.

  11. My question is not addressed here, how can I contact Technical Service for assistance?

    Ask a Scientist here.

Jane E Libbey et al.
Vaccine, 29(17), 3356-3362 (2010-09-21)
Experimental autoimmune encephalomyelitis (EAE) is an experimental model for multiple sclerosis. EAE can be induced by inoculation with central nervous system (CNS) proteins or peptides emulsified in complete Freund's adjuvant. Protection from EAE, enhancement of EAE or subclinical priming for
Cornelis J M Melief
Journal of immunotherapy (Hagerstown, Md. : 1997), 35(3), 215-216 (2012-03-17)
Here, we review a novel vaccine modality, characterized by the administration of long (23 to 45 amino acids) synthetic peptides in incomplete Freund's adjuvant (mineral oil based, Montanide ISA-51), delivered subcutaneously. Such vaccines were first demonstrated to be much more
Production of EV71 vaccine candidates.
Chong P, Hsieh SY, Liu CC, et al.
Human Vaccines & Immunotherapeutics, 8 (2012)
Rui Kong et al.
Cell, 178(3), 567-584 (2019-07-28)
The vaccine-mediated elicitation of antibodies (Abs) capable of neutralizing diverse HIV-1 strains has been a long-standing goal. To understand how broadly neutralizing antibodies (bNAbs) can be elicited, we identified, characterized, and tracked five neutralizing Ab lineages targeting the HIV-1-fusion peptide
Samantha Burton et al.
Journal of virology, 93(7) (2019-01-18)
The goals of preclinical HIV vaccine studies in nonhuman primates are to develop and test different approaches for their ability to generate protective immunity. Here, we compared the impact of 7 different vaccine modalities, all expressing the HIV-1 1086.C clade
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique